Suppr超能文献

神经内分泌学杂志:胆囊收缩素作用的新位点。

The subfornical organ: a novel site of action of cholecystokinin.

机构信息

Hotchkiss Brain Institute, Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada; and.

出版信息

Am J Physiol Regul Integr Comp Physiol. 2014 Mar 1;306(5):R363-73. doi: 10.1152/ajpregu.00462.2013. Epub 2014 Jan 15.

Abstract

The subfornical organ (SFO) is an important sensory circumventricular organ implicated in the regulation of fluid homeostasis and energy balance. We investigated whether the SFO is activated by the hormone cholecystokinin (CCK). CCK₁ and CCK₂ receptors were identified in the SFO by RT-PCR. Dissociated SFO neurons that responded to CCK (40/77), were mostly depolarized (9.2 ± 0.9 mV, 30/77), but some were hyperpolarized (-7.3 ± 1.1 mV, 10/77). We next examined the responses of SFO neurons in vivo to CCK (16 μg/kg ip), in the presence and absence of CCK₁ or CCK₂ receptor antagonists (devazepide; 600 μg/kg and L-365,260; 100 μg/kg, respectively), using the functional activation markers c-Fos and phosphorylated extracellular signal-related kinase (p-ERK). The nucleus of the solitary tract (NTS) served as a control for CCK-induced activity. There was a significant increase in c-Fos expression in the NTS (259.2 ± 20.8 neurons) compared with vehicle (47.5 ± 2.5). Similarly, in the SFO, c-Fos was expressed in 40.5 ± 10.6 neurons in CCK-treated compared with 6.6 ± 2.7 in vehicle-treated rats (P < 0.01). Devazepide significantly reduced the effects of CCK in the NTS but not in SFO. L-365,260 blocked the effects of CCK in both brain regions. CCK increased the number of p-ERK neurons in NTS (27.0 ± 4.0) as well as SFO (18.0 ± 4.0), compared with vehicle (8.0 ± 2.6 and 4.3 ± 0.6, respectively; P < 0.05). Both devazepide and L-365,260 reduced CCK-induced p-ERK in NTS, but only L-365,260 reduced it in the SFO. In conclusion, the SFO represents a novel brain region at which circulating CCK may act via CCK₂ receptors to influence central autonomic control.

摘要

神经内分泌研究所(SFO)是一种重要的感觉室周器官,参与调节液体平衡和能量平衡。我们研究了 SFO 是否被激素胆囊收缩素(CCK)激活。通过 RT-PCR 鉴定了 SFO 中的 CCK₁和 CCK₂受体。对 CCK(40/77)有反应的分离 SFO 神经元大多数被去极化(9.2 ± 0.9 mV,30/77),但有些被超极化(-7.3 ± 1.1 mV,10/77)。接下来,我们检查了在体 SFO 神经元对 CCK(16 μg/kg ip)的反应,在存在和不存在 CCK₁或 CCK₂受体拮抗剂(devaZepide;600 μg/kg 和 L-365,260;100 μg/kg)的情况下,使用功能激活标志物 c-Fos 和磷酸化细胞外信号相关激酶(p-ERK)。孤束核(NTS)作为 CCK 诱导活性的对照。与载体(47.5 ± 2.5)相比,NTS 中的 c-Fos 表达显着增加(259.2 ± 20.8 个神经元)。同样,在 CCK 处理的 SFO 中,与载体处理的大鼠(6.6 ± 2.7)相比,c-Fos 表达于 40.5 ± 10.6 个神经元中(P <0.01)。devaZepide 显着降低了 NTS 中 CCK 的作用,但在 SFO 中没有。L-365,260 阻断了这两个脑区中 CCK 的作用。CCK 增加了 NTS(27.0 ± 4.0)和 SFO(18.0 ± 4.0)中 p-ERK 神经元的数量,与载体(8.0 ± 2.6 和 4.3 ± 0.6,分别;P <0.05)。devaZepide 和 L-365,260 均降低了 NTS 中 CCK 诱导的 p-ERK,但只有 L-365,260 降低了 SFO 中的 p-ERK。总之,SFO 是一种新的脑区,循环 CCK 可能通过 CCK₂受体作用于该脑区以影响中枢自主控制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验